1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2 -mutant non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Liu, S. Y.; Jee, J.; Santini, F. C.; Schoenfeld, A. J.; Eichholz, J.; Johnson, K.; Martinez, A.; Guo, J.; Riaz, N.; Lee, N. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Oncologists' receipt of pharmaceutical industry payments and use of non-recommended and low-value cancer care services
    Meeting Abstract

    Mitchell, A. P.; Dusetzina, S. B.; Mishra Meza, A.; Trivedi, Niti U.; Bach, P. B.; Winn, A. N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Commercial vs. Medicaid insurance and use of high-priced anticancer treatments
    Meeting Abstract

    Mitchell, A. P.; Kinlaw, A. C.; Peacock Hinton, S.; Dusetzina, S. B.; Sanoff, H. K.; Lund, J. L.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Big data in oncology: Challenges and solutions
    Meeting Abstract

    Shah, N. J.; Bahadur, N.; Niederhausern, A.; Insinga, A.; Shah, I.; West, G.; Ahmad, H.; Martin, S.; Watson, A.; Nichols, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19)
    Meeting Abstract

    Aggarwal, R. R.; Dooley, K.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial
    Meeting Abstract

    McKay, R. R.; Xie, W.; Yang, X.; Rathkopf, D. E.; Laudone, V. P.; Bubley, G.; Einstein, D. J.; Chang, P.; Wagner, A.; Kane, C. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC)
    Meeting Abstract

    Halabi, S.; Guo, S. S.; Roy, A.; Rydzewska, L.; Godolphin, P.; Hussain, M. H. A.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Tumor dosimetry of [(177)Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study
    Meeting Abstract

    Krause, B. J.; Chi, K. N.; Sartor, A. O.; Fizazi, K.; Morris, M. J.; De Bono, J. S.; Tagawa, S. T.; Herrmann, K.; Kurth, J.; Eiber, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
    Meeting Abstract

    Halabi, S.; Roy, A.; Guo, S. S.; Rydzewska, L.; Godolphin, P.; Hussain, M. H. A.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide
    Meeting Abstract

    Guo, S. S.; Halabi, S.; Nanus, D. M.; George, D. J.; Antonarakis, E. S.; Danila, D. C.; Szmulewitz, R. Z.; McDonnell, D. P.; Norris, J. D.; Lu, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save